| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(5 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(7 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US11707479 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
|
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
|
US11707479 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
|
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
Epclusa is owned by Gilead Sciences Inc.
Epclusa contains Sofosbuvir; Velpatasvir.
Epclusa has a total of 32 drug patents out of which 0 drug patents have expired.
Epclusa was authorised for market use on 19 March, 2020.
Epclusa is available in tablet;oral, pellets;oral dosage forms.
Epclusa can be used as for the treatment of hepatitis c.
Drug patent challenges can be filed against Epclusa from 11 December, 2027.
The generics of Epclusa are possible to be released after 30 July, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| M(M-264) | Jul 14, 2023 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| M(M-277) | Apr 27, 2025 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Strength(NS) | Mar 19, 2023 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL; PELLETS;ORAL
EPCLUSA family patents
